Uncategorized Archives

MondayApr 22, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval

Lexaria, a global innovator in drug delivery platforms, has received approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board GLP-1 drugs are utilized in the treatment of type 2 diabetes and obesity, a huge market, and are typically administered by painful and expensive injection, offering a major opportunity for Lexaria’s oral delivery platform This approval sets the company up for dosing within 30 days or less, with tentative study completion dates for this summer The study will comprise two study arms, the second study arm will investigate whether Lexaria’s patented DehydraTECH(TM)-enhanced semaglutide can effectively…

ThursdayApr 18, 2024 9:45 am

Software Effective Solutions Corp. (SFWJ) Subsidiary Inks Major Deal with Danziger Colombia

New three-year agreement between SFWJ’s Eko2o and Danziger Colombia reflects both companies’ commitment to sustainable, innovative agriculture practices The collaboration is projected to generate $2.5–$3 million in revenue over the next three years Eko2o will provide greenhouse infrastructure services, irrigation products and technology to Danziger’s flower operations in Colombia Agriculture can have a significant impact on the environment, and an increasing number of companies are working to ensure their agricultural practices are sustainable. Software Effective Solutions (OTC: SFWJ) is among that group, with its majority-controlled, Colombia-based subsidiary Eko2o S.A.S entering a major multiyear contract with Danziger Colombia (https://cnw.fm/apRCJ), the world’s…

TuesdayApr 16, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024

Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41 Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended Lexaria’s management plans to maintain focus on GLP-1 studies for 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally to 41, a testament to the versatility of its patented DehydraTECH(TM) technology…

FridayApr 12, 2024 11:15 am

Golden Triangle Ventures Inc. (GTVH) Announces CEO Interview Series, Partners with Consulting Company on Flagship Destino Ranch Project

CEO interview series provides Golden Triangle with a platform to share its story with an expanded audience Collaboration with Cayenne Consulting will provide key strategic planning and expertise in development of Destino Ranch Destino Ranch aims to redefine luxury entertainment and hospitality experiences As Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment, focus on the development of Destino Ranch, a one-of-a-kind immersive entertainment venue, the company is working to increase awareness of the project. As part of these efforts, Golden Triangle is partnering with NowMedia Networks to broadcast 12 weekly interviews with GTVH CEO and president Steffan…

ThursdayApr 11, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment

Lexaria, a global innovator in drug delivery platforms, has announced the appointment of Nelson Cabatuan, CPA, as its new CFO Nelson will lend over 15 years of experience in corporate finance and operations, having worked in key organizations within the industry, and will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company The appointment highlights Lexaria’s confidence in its recently confirmed focus on important GLP-1 studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial…

WednesdayApr 10, 2024 9:00 am

Golden Triangle Ventures Inc. (GTVH) Making Key Progress in Development of Destino Ranch, an Immersive Entertainment Venue

Developed under Lavish Entertainment, a wholly owned subsidiary of GTVH, Destino Ranch will be a one-of-a-kind destination that revolutionizes the concept of an immersive music and art venue. Phase one development begins after the execution of a land-use-and-development agreement outlining exclusive rights to purchase, use and operate the nearly 70-acre property. Additional upgrades on the initial property secured will “dramatically increase speed into the market.” Marco Moreno has been appointed as president of Lavish Entertainment to spearhead the development of Destino Ranch. Mr. Moreno has notable experience in the large-scale event development industry with high-fidelity collaborations through his company ABI…

MondayMar 25, 2024 12:45 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, recently hired a Contract Research Organization to perform their second GLP-1 human pilot study which will test a dissolvable DehydraTECH-GLP-1 oral dose formulation The announcement follows Lexaria’s WEIGHT-A24-1 animal study announcement examining diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and cannabidiol alone and in combination The move aligns with the company’s resolve to focus on their ability to enhance the delivery of GLP-1 diabetes and obesity drugs At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double down…

MondayMar 25, 2024 12:00 pm

Software Effective Solutions Corp. (SFWJ) Completes Key Acquisitions, Is Committed to Becoming Cannabis Market Leader

MedCana adds to portfolio with strategic acquisition of two cannabis companies First acquisition represents “leap forward” in SFWJ’s commitment to innovation, excellence within the cannabis sector Second company holds key production, processing and exportation licenses that will strengthen MedCana’s operational chain Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is growing its footprint in the cannabis space through savvy acquisitions. In the past few months, MedCana, a leading holding company in the cannabis industry, has announced two new acquisitions as the company keeps its eye on making strategic additions to its portfolio. Last month, the company announced that it was in the…

ThursdayMar 21, 2024 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss; Sets Stage for 8-week Diabetes and Weight Loss Animal Study

Lexaria, a global innovator in drug delivery platforms, highlighted results from its DIAB-A22-1 animal study, highlighting a 7% reduction in weight and a 19.9% reduction in blood glucose With this success, Lexaria looks to kick off its WEIGHT-A24-1 animal study to examine diabetes and weight loss effects of its patented DehydraTECH(TM)-processed GLP-1 drugs and DehydraTECH-processed CBD The study will comprise 12 arms and involve 72 animals. It will run for a total of 12 weeks This study will build on previous studies that evidenced DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue Lexaria Bioscience (NASDAQ:…

MondayMar 18, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Huge 2024 Milestone with FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the…

News and publishing service for CBD related companies

Contact us: 303.498.7722

Category: Uncategorized